Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (400)	12/12/1997 12:21:00 PM
From: Sector Investor	Read Replies (1) \| Respond to of 887

As I promised, this information from SBC Warburg Dillon Reed (DR) 12/10: DEPO: Initiates Phase II DepoMorphine Trial Rating: Buy DR says that DepoTech announced yesterday that it commenced Phase II trials of DepoMorphine for acute post-operative pain. They say that the Phase II dose-escalation study will involve 60-90 patients and will evaluate safety, efficacy and pharmacokinetics of single doses administered epidurally prior to surgery. DepoMorphine is being studied for use in, but not limited to, such procedures as abdominal, orthopedic and thoracic surgeries, among others. DR adds that DepoMorphine, a sustained-release DepoFoam formulation of the opiate morphine, is designed to provide two to four days of pain relief after epidural administration. Phase I results involving healthy volunteers reached a maximum tolerated dose of 30mg. Current treatment with morphine sulfate consists of between 2 mg and 10 mg in a 24-hour period. The Phase I trial as well as toxicology studies in animals indicate that a single epidural injection of DepoMorphine can provide effective analgesia for as long as four days. DR's Outlook: DR comments that DepoMorphine is the company's third product in development and may provide a new alternative in the large market of post-operative pain management. DepoCyt, the company's lead product, is scheduled for review at the December 18 Oncologic Advisory Committee meeting and DR expects a positive outcome, with product sales beginning in mid-1998. DR believes that DepoTech shares are currently undervalued based on the potential for DepoCyt and the planned aggressive development of its earlier- stage products. DR continues to recommend purchase of DepoTech shares with a Buy rating. DR has 2 analysts covering DEPO. They state that this report includes information obtained from sources believed to be reliable but no independent verification has been made, and they do not guarantee its accuracy or completeness. DR also says that opinions expressed are subject to change without notice.

To: chirodoc who wrote (400)	12/12/1997 12:27:00 PM
From: Sector Investor	Read Replies (1) \| Respond to of 887

Don't know if this was posted: DepoTech Begins Phase II Clinical Trial For DepoMorphine Business Wire via Dow Jones SAN DIEGO--(BW HealthWire)--Dec. 9, 1997--DepoTech Corp. (Nasdaq: DEPO) Tuesday announced that it has begun Phase II clinical studies of DepoMorphine, sustained-release encapsulated morphine sulfate being developed to treat acute post-surgical pain. Based on DepoFoam technology, DepoMorphine is targeted at patients following a broad range of surgeries, including deep abdominal, thoracic, and orthopedic procedures. The Phase II clinical trials are dose-escalation studies that will assess safety, efficacy and pharmacokinetics of DepoMorphine administered epidurally to patients prior to a variety of surgical procedures. A total of 60 to 90 patients will be enrolled in these studies. A recently completed Phase I clinical trial showed that DepoMorphine, when administered in normal volunteers, reached a maximum tolerated dose of 30 mg. Current treatment with un-encapsulated morphine sulfate consists of between 2 and 10 mg of drug over the first 24 hours. Pharmacokinetic data from preclinical studies and the Phase I clinical trial indicate that morphine is present in subjects for a prolonged period following DepoMorphine administration. DepoMorphine can potentially offer two to three days of pain relief using a single dose. "DepoMorphine may offer a new therapeutic alternative in post-operative pain management," said Edward L. Erickson, DepoTech's president and chief executive officer. "Initiation of Phase II trials is an important step towards adding new drugs to DepoTech's product base." The DepoFoam drug delivery system is composed of microscopic, spherical particles that can be used to encapsulate a variety of medically important compounds. A lipid-based formulation, DepoFoam particles are non-toxic and biodegradable and, to date, have been shown to be well-tolerated in patients. When injected into the body, DepoFoam formulations generally provide sustained release of the active drug which should allow for less frequent dosing. DepoTech is a drug delivery company dedicated to the development and manufacture of innovative, sustained-released therapeutic products based on DepoFoam technology. Products are being developed to satisfy medical needs in cancer, infectious diseases, pain management and other fields. The company has filed a New Drug Application with the U.S. Food and Drug Administration for its lead product, DepoCyt, an anti-cancer drug for the treatment of neoplastic meningitis. This news release contains forward-looking statements regarding DepoTech Corp.'s programs. Actual results could differ materially from those described in this news release as a result of a number of factors, including, but not limited to the following: There can be no assurance that any product in the DepoTech product pipeline will be successfully developed or manufactured, or that final results of human clinical trials will be supportive of regulatory approvals required to market products, or that final regulatory approval will be received in a timely manner, if at all, or that patient and physician acceptance of these products will be achieved. The company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this release. DepoTech is a registered trademark of DepoTech Corp. Additional written materials and recent releases regarding DepoTech are available on the World Wide Web at depotech.com . CONTACT: DepoTech Corp., San Diego Edward L. Erickson, 619/625-2424 or StratiPoint Group Mike Jackman, 415/388-3216 09:33 EST DECEMBER 9, 1997